Olivier Moranne
Prof Olivier Moranne is an expert in Nephrology at Centre Hospitalier Universitaire de Nîmes (France). As of October 2026, ScienceLeadR ranks Olivier Moranne in the top 1% of experts worldwide for Renal Insufficiency. Olivier Moranne has authored 301 publications, the most recent in 2026, and is an investigator in 44 clinical trials, 18 of them ongoing. SLR score: 1,731 (community average: 125). How the SLR is computed.
LeadR Profile
Nephrology
Subspecialties: Hematology - Transplantation - Urology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2003 - 2026
Number : 301
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Centrifugal Plasma Exchange Versus Double-Filtration Plasmapheresis in Chronic CIDP: A Randomized Crossover Study Comparing Clinical Outcomes, Biological Effects, Procedure Times, and Costs-The Lymphoapheresis Study. PMID 42844560 — plasma volume, blood, hospital costs, cross-over studies, plasmapheresis, polyradiculoneuropathy, chronic inflammatory demyelinating, plasma exchange, therapeutics, plasma | J Clin Apher | 2026 | 0 |
| Challenges and strategies for managing early-to-moderate chronic kidney disease in primary care: A systematic integrative review in high-income countries. PMID 42554240 — kidney diseases, guideline adherence, income, family practice, kidney, education | Eur J Gen Pract | 2026 | 0 |
| Real-time, Multidisciplinary Approach of Women With Pregnancy-Associated Thrombotic Microangiopathy. PMID 42502667 — thrombotic microangiopathies, pregnancy, pre-eclampsia, therapeutics, postpartum period, acute kidney injury | Kidney Int Rep | 2026 | 0 |
| Outcomes and Predictors of Treatment Response in Patients With Pure Lupus Membranous Nephropathy. PMID 42494786 — glomerulonephritis, membranous, antibodies, duration of therapy, treatment failure, lupus erythematosus, systemic, rituximab, therapeutics, steroids, mycophenolic acid | Kidney Int Rep | 2026 | 0 |
| Kidney histopathology associated with kidney function at 1 year post severe AKI related to ANCA-associated vasculitis. PMID 42449260 — kidney diseases, vasculitis, kidney, biopsy, plasmapheresis, plasma exchange, anti-neutrophil cytoplasmic antibody-associated vasculitis, therapeutics, prognosis, plasma | BMC Nephrol | 2026 | 1 |
Clinical Studies 44
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 10
Ongoing Clinical Trials
18 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| A trial to learn how well baxdrostat with dapagliflozin works compared to dapagliflozin alone and how safe it is in adults with chronic kidney disease (CKD) and high blood pressure 2023-506457-38-00 — kidney diseases, hypertension, safety, blood, blood pressure, double-blind method, kidney | Phase 3 | Active not recruiting | 2024 |
| A study to find out if BI 764198 helps adults and adolescents with a kidney condition called focal segmental glomerulosclerosis (FSGS) 2025-522191-86-00 — genes, kidney, adolescent, glomerulosclerosis, focal segmental, therapeutics, trpc6 cation channel | Phase 3 | Not yet recruiting | 2026 |
| A trial to learn how well baxdrostat with dapagliflozin works compared to dapagliflozin on clinical outcomes alone and how safe it is in adults with chronic kidney disease (CKD) and high blood pressure 2023-506460-14-00 — kidney diseases, hypertension, mortality, safety, blood, blood pressure, kidney | Phase 3 | Recruiting | 2025 |
| Trial to Evaluate the Long term Safety and Efficacy of Avacopan in participants With ANCA associated Vasculitis 2023-503184-42-00 — vasculitis, safety, anti-neutrophil cytoplasmic antibody-associated vasculitis, antibodies, antineutrophil cytoplasmic | Phase 4 | Not yet recruiting | 2025 |
| A multicenter phase 2 single arm proof of concept trial assessing the efficacy and safety of Obinutuzumab in the treatment of non infectious active cryoglobulinemia vasculitis refractory or intolerant to Rituximab 2023-508930-33-00 — vasculitis, safety, cryoglobulinemia, rituximab, therapeutics | Phase 2 | Recruiting | 2026 |
LeadR Networks
Main global connection map